PBC is a rare autoimmune liver disease that slowly destroys bile ducts. With ursodiol and newer second-line therapies, most patients can halt progression and live normal lives — if caught early.
PBC affects roughly 1 in 1,000 women over 40. It's often discovered incidentally on routine liver enzyme tests.
🕐 Last updated: March 23, 2026📡 Sources: NIH · CDC · FDA · ClinicalTrials.gov12 articles
🔔
Get PBC Alerts
Free weekly updates from NIH, CDC & FDA when new research drops. No spam. Unsubscribe anytime.
NIHJune 15, 2024
Fibrates for PBC: Bezafibrate and Elafibranor as Second-Line Options
Fibric acid derivatives (fibrates) — a class of drugs primarily used for high triglycerides — have emerged as a promising second-line option for PBC patients who respond inadequately to UDCA. Their mechanism in PBC involves PPARα activation, which reduces bile acid synthesis and improves biliary secretion.
Bezafibrate has the longest clinical history. Multiple Japanese studies and the European BEZURSO trial showed bezafibrate combined with UDCA achieved the Paris II biochemical response criteria in 31% of inadequate UDCA responders vs. 0% with placebo, along with significant ALP normalization in some patients. It's not FDA-approved for PBC and is unavailable in the US, but is used off-label in Europe and Asia. The dose studied is 400 mg/day.
Elafibranor (Iqirvo) is a next-generation dual PPARα/δ agonist developed specifically for PBC. The ELATIOND Phase 3 trial reported a 51% composite response rate at 52 weeks vs. 19% for placebo — leading to FDA approval in June 2024 as a second-line add-on to UDCA. It's taken as a once-daily 80 mg oral tablet. Unlike obeticholic acid, it doesn't appear to worsen pruritus. Side effects include headache and abdominal pain. It's indicated for adults with inadequate response or intolerance to UDCA, positioning it alongside seladelpar as an alternative second-line choice.
The PBC treatment pipeline is more active in 2026 than at any previous point, driven by the approval of seladelpar and several late-stage agents.
Key ongoing trials: Linerixibat (GSK), an ileal bile acid transporter (IBAT) inhibitor, is in Phase 2b/3 for PBC-related pruritus — a mechanism specifically designed to block bile acid reabsorption and reduce pruritus without systemic drug effects. Early results show significant itch reduction. Elafibranor (Ipsen), a dual PPARα/δ agonist, completed Phase 3 (ELATIOND trial) showing strong biochemical response with favorable safety for second-line PBC. Bezafibrate, already used in some European countries off-label, is being studied in combination with UDCA in the BEZURSO-2 and FITCH trials.
Next-generation targets include the GPBAR1/TGR5 receptor, FGF19 analogs (aldafermin), and anti-NKT therapies addressing the autoimmune bile duct attack directly. The goal: move beyond biochemical markers to histological endpoints (fibrosis reversal) and ultimately disease modification. Patients interested in trials can search ClinicalTrials.gov for "primary biliary cholangitis" and contact the American Liver Foundation (liverfoundation.org) for patient matching to open studies.
Fatigue is the most prevalent symptom in PBC, affecting 50–85% of patients. Unlike pruritus or liver function deterioration, PBC-related fatigue does not always correlate with disease severity — some patients with mild biochemical disease have severe fatigue, while others with cirrhosis function well. This makes it frustrating to treat and often dismissed by clinicians.
The mechanism is thought to involve autonomic dysfunction, altered serotonin and corticotropin-releasing hormone signaling, and social/psychological factors amplified by the chronic disease burden. PBC-related fatigue is distinct from the fatigue of anemia, hypothyroidism, or depression — though all three are more common in PBC patients and must be ruled out and treated first.
Evidence-based interventions: treat underlying hypothyroidism (Sjögren's syndrome-related, common in PBC). Screen for depression. Graded exercise therapy has modest evidence for PBC fatigue. Rituximab and modafinil have been studied but not shown to improve PBC fatigue in RCTs. Cognitive behavioral therapy (CBT) has the best evidence for improving quality of life in PBC-associated fatigue. Managing sleep disturbance (often co-occurring with pruritus) is critical. The PBC Foundation (pbcers.org) offers peer support specifically addressing fatigue management strategies.
Liver Transplant Criteria for PBC: When Is It Needed?
Liver transplantation is the definitive treatment for PBC patients who develop end-stage liver disease or complications of portal hypertension. With modern therapies, the proportion of PBC patients who progress to transplant has declined significantly — but it remains the only curative option for decompensated disease.
Indications for transplant evaluation in PBC: Model for End-Stage Liver Disease (MELD) score ≥15, refractory ascites unresponsive to diuretics, recurrent variceal hemorrhage, hepatic encephalopathy, spontaneous bacterial peritonitis, rising bilirubin >6 mg/dL despite treatment, and — importantly — refractory pruritus causing intractable suffering even with preserved synthetic function (PBC is one of the few diseases where transplant can be listed for intractable pruritus before MELD criterion).
Outcomes after liver transplant for PBC are excellent — better than most other indications. Five-year survival exceeds 80–85%. PBC can recur in the transplanted liver (in ~25% at 10 years) but rarely leads to graft failure. Patients should be referred to a transplant center when MELD begins rising above 12–15, not as a last resort. Early listing provides more time for pre-transplant optimization and appropriate organ allocation.
PBC during pregnancy requires careful management and close collaboration between hepatology and obstetrics. The key question most patients have: can I take my PBC medications while pregnant, and what risks does PBC pose to the pregnancy?
UDCA: The safety data for UDCA in pregnancy is generally reassuring. It is the only approved PBC therapy with enough pregnancy exposure data to inform decision-making. Most guidelines recommend continuing UDCA throughout pregnancy given the risk of stopping treatment, as hepatic flares during pregnancy can be severe. UDCA is listed as FDA Category B (animal studies show no risk; human studies inadequate but drug widely used without apparent harm).
Second-line therapies (obeticholic acid, seladelpar): Pregnancy data is very limited. Both should generally be discontinued before conception and avoided during pregnancy. If a patient becomes pregnant on these therapies, immediate hepatology consultation is required. PBC itself can worsen during or after pregnancy — particularly postpartum. Cholestatic jaundice of pregnancy (intrahepatic cholestasis of pregnancy, ICP) has higher incidence in women with underlying PBC. All pregnant PBC patients require 4-week follow-up monitoring with LFTs and close obstetric co-management.
Approximately 8–10% of patients with PBC also show features of autoimmune hepatitis (AIH) — a condition known as AIH-PBC overlap syndrome. This matters because the two diseases require different treatments: UDCA for PBC versus immunosuppression (corticosteroids, azathioprine) for AIH. Missing the overlap means undertreatment of one component.
The Paris criteria are most commonly used to diagnose AIH-PBC overlap: at least 2 of 3 AIH criteria (ALT ≥5× ULN, IgG ≥2× ULN or positive smooth muscle antibodies, liver biopsy showing moderate-severe hepatitis) plus at least 2 of 3 PBC criteria (ALP ≥2× ULN, positive AMA, liver biopsy with florid bile duct lesions).
Treatment for confirmed AIH-PBC overlap typically combines UDCA plus immunosuppression with prednisolone, with or without azathioprine. The challenge: distinguishing true overlap from PBC with incidental interface hepatitis (which may resolve with UDCA alone) vs. true AIH-PBC overlap. Liver biopsy is usually required. Patients with overlap syndrome tend to have more aggressive disease and worse fibrosis stage at diagnosis — making early biopsy and accurate classification important.
Pruritus in PBC: Managing the Itch That Won't Quit
Cholestatic pruritus — itch caused by impaired bile flow — affects 20–70% of PBC patients and is frequently cited as the most debilitating symptom. It's not just mild irritation: severe PBC pruritus can be constant, generalized (often worse in the evening and night), and refractory to standard antihistamines that work for allergic itch.
The mechanism differs from allergic itch. Cholestatic pruritus is mediated by bile salt accumulation and endogenous opioid signaling in the nervous system — which is why antihistamines are largely ineffective. Evidence-based treatments include cholestyramine (binds bile salts in the intestine; effective but poorly tolerated due to taste and constipation), rifampicin (induces hepatic metabolism of pruritogens; highly effective; 2nd-line), naltrexone (opioid antagonist; useful for refractory cases), and sertraline (4th-line, modest evidence).
Newer options: bezafibrate (a fibrate that may reduce both ALP and pruritus) and linerixibat (an ileal bile acid transporter inhibitor in Phase 2/3) show promise. Seladelpar has demonstrated significant pruritus reduction in trials — an advantage over obeticholic acid which often worsens it. For severe refractory pruritus unresponsive to medical therapy, consider referral to a hepatologist with specific cholestatic disease expertise, as plasmapheresis, molecular adsorbent recirculating system (MARS) dialysis, or early transplant evaluation may be appropriate.
ALP and Bilirubin: Understanding PBC Monitoring Tests
Two lab values dominate PBC monitoring: alkaline phosphatase (ALP) and total bilirubin. Together, they tell your doctor how well your bile ducts are functioning, how well you're responding to treatment, and how much disease progression risk remains.
Alkaline phosphatase (ALP) is the most sensitive early marker of PBC activity. Elevated ALP reflects cholestasis — bile duct dysfunction and impaired bile flow. In PBC, ALP often runs 2–10× the upper limit of normal (ULN) at diagnosis. A key treatment goal is getting ALP below 1.5× ULN (ideally to normal), since persistently elevated ALP predicts progression to fibrosis and cirrhosis.
Total bilirubin is the most important prognostic marker in PBC. Normal bilirubin is less than 1.0 mg/dL. Rising bilirubin signals that the liver is struggling to process the backlog of bile and is the single strongest predictor of need for transplant listing. The Mayo PBC risk score and GLOBE score incorporate bilirubin prominently. Beyond ALP and bilirubin, GGT (gamma-glutamyl transferase), ALT, AST, albumin, platelet count, and INR are monitored to track overall liver synthetic function and detect cirrhosis development.
Ursodiol (UDCA) for PBC: First-Line Treatment Explained
Ursodeoxycholic acid (ursodiol, UDCA) has been the cornerstone of PBC treatment for over 30 years and remains the recommended first-line therapy per all major liver society guidelines. It's a naturally occurring bile acid that works by displacing more toxic hydrophobic bile acids, improving bile flow, and exerting anti-inflammatory effects on bile duct cells.
The standard dose is 13–15 mg/kg/day, typically divided into two doses taken with food. UDCA is generic and inexpensive (often $10–$30/month) and is generally well-tolerated. The most common side effects are loose stools and mild weight gain. Most patients tolerate it without issue for years.
The critical clinical point: treatment response to UDCA — measured at 1 year — strongly predicts long-term outcomes. Various response criteria are used (Paris I, Paris II, Barcelona, Toronto), but most agree that ALP < 1.5–2× upper limit of normal (ULN) and total bilirubin within normal range indicates good response. Approximately 60–70% of PBC patients respond adequately to UDCA alone. The remaining 30–40% are "UDCA inadequate responders" and qualify for second-line therapy (seladelpar or obeticholic acid).
Ocaliva Safety Update: PBC Liver Risk and Who Should Reconsider
Obeticholic acid (Ocaliva, Intercept) was FDA-approved in 2016 for PBC patients with inadequate response to UDCA or who cannot tolerate UDCA. It's a farnesoid X receptor (FXR) agonist that reduces bile acid synthesis and improves bile flow. However, the FDA has issued important safety communications since approval.
The primary concern: Ocaliva carries a boxed warning for serious liver injury in patients with moderate to severe cirrhosis (Child-Pugh B or C) or with evidence of decompensation. Ocaliva is contraindicated in complete biliary obstruction. Cases of liver failure and death have occurred in cirrhotic PBC patients who received incorrect dosing. The correct dose for cirrhosis patients is 5 mg once weekly, not daily — a critical distinction.
For non-cirrhotic patients who respond to Ocaliva (ALP reduction ≥15%), it remains a reasonable second-line option. The most common side effect is worsening pruritus, which affects up to 77% of patients to some degree and is dose-dependent. New itch management strategies or dose reduction often help. If you have cirrhosis or decompensated liver disease and were prescribed Ocaliva daily, speak with your hepatologist immediately about whether the dosing is appropriate or whether seladelpar is a better alternative.
Seladelpar Approval for PBC: What Patients Need to Know
Seladelpar (Livdelzi, Gilead) was approved by the FDA in August 2024 as the first peroxisome proliferator-activated receptor delta (PPARδ) agonist for PBC — a new drug class for a condition that had only one other recently approved second-line therapy (obeticholic acid). It's indicated for adults with PBC who have had an inadequate response or are intolerant to ursodeoxycholic acid (UDCA).
The approval was based on the RESPONSE Phase 3 trial, which enrolled 193 patients with inadequate response to UDCA. At 12 months, 61.7% of seladelpar-treated patients achieved the composite endpoint (ALP < 1.67× ULN, total bilirubin ≤ ULN, and ALP reduction ≥ 15%) compared to 20% on placebo. Crucially, seladelpar showed significant improvement in pruritus — one of the most debilitating PBC symptoms — where obeticholic acid can actually worsen itch.
The recommended dose is 10 mg once daily by mouth. Unlike obeticholic acid, seladelpar does not appear to worsen pruritus and carries no boxed warning for hepatic decompensation in cirrhotic patients (though close monitoring is still warranted). Common side effects include abdominal discomfort, nausea, and fatigue. Access: typically requires prior authorization documenting UDCA inadequate response.
What Is Primary Biliary Cholangitis (PBC)? Understanding Your Diagnosis
Primary biliary cholangitis (PBC), formerly called primary biliary cirrhosis, is a chronic autoimmune liver disease in which the immune system attacks the small bile ducts inside the liver. When these ducts are destroyed, bile accumulates in the liver — a condition called cholestasis — causing progressive inflammation and scarring. Over years to decades, untreated or poorly controlled PBC can lead to cirrhosis and liver failure.
PBC predominantly affects women (90% of cases), typically diagnosed between ages 40 and 60, though men and younger people are also diagnosed. The hallmark blood test finding is a positive antimitochondrial antibody (AMA), present in about 95% of PBC patients, along with elevated alkaline phosphatase (ALP). Most patients are diagnosed incidentally when routine blood work reveals abnormal liver enzymes.
The prognosis for PBC has dramatically improved with effective therapies. Patients who respond well to ursodiol and maintain normal or near-normal ALP and bilirubin levels have life expectancy comparable to the general population. The key is early diagnosis and treatment before significant fibrosis or cirrhosis develops.
My Sugar Pill may earn a commission when you book — at no extra cost to you. One way we keep My Sugar Pill free.
About this content
Sourced from U.S. government health agencies (NIH, CDC, FDA) and ClinicalTrials.gov. Summaries are written in plain English. Always consult your doctor before making healthcare decisions. My Sugar Pill does not provide medical advice.
About My Sugar Pill · No sponsored content · No data selling · Free, always.